ORIGINAL ARTICLE INTRODUCTION

Size: px
Start display at page:

Download "ORIGINAL ARTICLE INTRODUCTION"

Transcription

1 Arthritis Care & Research Vol. 65, No. 2, February 2013, pp DOI /acr , American College of Rheumatology ORIGINAL ARTICLE Foot-Related Health Care Use in Patients With Rheumatoid Arthritis in an Outpatient Secondary Care Center for Rheumatology and Rehabilitation in The Netherlands: A Cohort Study With a Maximum of Fifteen Years of Followup ANNEKE F. MARSMAN, 1 RUTGER DAHMEN, 1 LEO D. ROORDA, 1 DIRKJAN VAN SCHAARDENBURG, 2 JOOST DEKKER, 2 KARIN BRITSEMMER, 1 DIRK L. KNOL, 3 AND MARIKE VAN DER LEEDEN 2 Objective. To describe foot-related health care use over time in a cohort of rheumatoid arthritis (RA) patients in an outpatient secondary care center for rheumatology and rehabilitation in The Netherlands. Methods. A total of 1,087 patients with recent-onset RA from 1995 to September 2010 were included in the study. All foot-related visits to the podiatrist, rehabilitation physician, orthopedic surgeon, and the multidisciplinary foot-care clinic were registered and described. Logistic regression techniques for longitudinal data were used to analyze the course of foot-related health care use. Results. A total of 32.9% of patients visited a podiatrist in secondary care during the course of their disease. For most patients, a visit to the podiatrist took place during the first year after diagnosis. This was followed by a significant decrease in visits in the ensuing years. Nine percent of patients visited the rehabilitation physician with foot symptoms, with peak prevalences between year 10 and 11 and during year 14 of followup. The orthopedic surgeon was visited by 5.3% of patients with foot symptoms, with a significant increase in visits over time. The multidisciplinary foot-care clinic was visited by 7.5% of patients. This was significantly associated with visits to the rehabilitation physician. Conclusion. In an outpatient secondary care center in The Netherlands, RA patients with foot symptoms visited the podiatrist in an early stage of the disease. When foot symptoms worsened, patients visited the rehabilitation physician, who subsequently referred patients to the multidisciplinary foot-care clinic for therapeutic footwear. The orthopedic surgeon was the final step in the management of foot symptoms. INTRODUCTION Foot symptoms are a common feature of rheumatoid arthritis (RA). As many as 90% of RA patients experience foot symptoms at some point in the course of their disease (1). At disease onset, it is predominantly the metatarsophalangeal (MTP) joints that develop synovitis, leading to 1 Anneke F. Marsman, BSc, Rutger Dahmen, MD, Leo D. Roorda, MD, PT, PhD, Karin Britsemmer, MD: Reade, Amsterdam, The Netherlands; 2 Dirkjan van Schaardenburg, MD, PhD, Joost Dekker, PhD, Marike van der Leeden, PT, PhD: Reade and VU University Medical Center, Amsterdam, The Netherlands; 3 Dirk L. Knol, PhD: VU University Medical Center, Amsterdam, The Netherlands. Address correspondence to Marike van der Leeden, PT, PhD, Amsterdam Rehabilitation Research Center, Reade, PO Box 58271, 1040 HG Amsterdam, The Netherlands. m.vd.leeden@reade.nl. Submitted for publication March 16, 2012; accepted in revised form June 22, pain and swelling of the forefoot. In turn, synovitis of the MTP joints can have a destructive impact on the quality and structure of the joints and surrounding soft tissues (2,3). Pain, swelling, and structural alterations of the foot can cause walking disabilities (4,5) and a decrease in quality of life (6,7). Data on the prevalence and course of forefoot impairments in the first 8 years following initial diagnosis of RA are available (2). These data show a rapid increase in the percentage of new patients presenting with erosions during the first 2 years after diagnosis, with a slight decline during the years that follow. The prevalence of pain and swelling of MTP joints is accordingly high in these first 2 postdiagnosis years, after which stabilization in the pain and swelling takes place. A relationship between the prevalence of foot impairments and health care use due to these foot impairments during the course of the disease is expected. The management of foot symptoms can be divided into pharmacologic and nonpharmacologic management. Phar- 220

2 RA and Foot-Related Health Care Use 221 Significance & Innovations The number of patients (n 1,087) and long followup duration (15 years) of this study made it possible to review foot-related health care use during the course of rheumatoid arthritis (RA). Patients visited the podiatrist in the early stage of the disease. When foot symptoms worsened, patients visited the rehabilitation physician, who subsequently referred patients to the multidisciplinary foot-care clinic for therapeutic footwear. The orthopedic surgeon was the final step in the management of foot symptoms. In view of the high prevalence of painful and swollen metatarsophalangeal joints early in the RA disease process, this study points out the possibility of underuse of care, which is an important target for future research. macologic management is mainly systemic, consisting of nonsteroidal antiinflammatory drugs, corticosteroids, and disease-modifying antirheumatic drugs (DMARDs) and biologic treatments (8,9). Nonpharmacologic management is mainly locally administered, and can be either conservative or surgical in nature. Conservative management, consisting of foot orthoses in nonprescription shoes or therapeutic footwear, aims to decrease foot pain and disability (9 11). Specific foot problems may require surgical treatment, such as severe subluxation of the MTP joints or severe hallux valgus (12). Until now, health care use in RA patients with foot symptoms has only been studied using a cross-sectional study design (5,12,13). Longitudinal data concerning the use of both conservative and surgical interventions are lacking. The knowledge of health care use due to foot symptoms may give relevant insight into the type and timing of foot-related interventions, which may ultimately be used to optimize foot care in RA. Therefore, the aim of the present study was to describe foot-related health care use over time in a cohort of RA patients in an outpatient secondary care center for rheumatology and rehabilitation in The Netherlands. PATIENTS AND METHODS Study design. Since 1995, patients ages 18 years and diagnosed with recent-onset arthritis (symptom duration of 3 years) have been included in an Early Arthritis Cohort (EAC) of Reade, an outpatient secondary care center for rheumatology and rehabilitation (14). This cohort was established in 1995 to study a wide variety of research topics, including the presence and course of the signs and symptoms of the disease process. The exclusion criteria for the EAC are having a history of treatment with DMARDs and the presence of 1 of the following comorbidities: crystal arthropathy, osteoarthritis, systemic lupus erythematosus, Sjögren s syndrome, infectious arthritis, and spondylarthropathy. As of September 2010, a total of 2,023 patients had been included and followed up in the EAC. The patients disease activity, joint damage (as scored by radiographs), and functional capacity were assessed at different time points. The drug treatment decisions were made by the rheumatologists according to clinical practice standards. Patient selection. In the present study, 1,087 patients (54% of the 2,023 patients included and followed up in the EAC) fulfilled the 1987 American College of Rheumatology criteria for RA (15) at baseline and/or 1 year after inclusion. For these patients, health care use related to foot symptoms was registered. As patients were included from 1995 until September 2010, the duration of followup between the patients varied (Figure 1). Data were available Figure 1. Schematic view of our research design. Values are the number of patients fulfilling the American College of Rheumatology criteria enrolled in the Early Arthritis Cohort (EAC) each year since Rheumatoid arthritis (RA) patients registered in September 2010 were included in the present study (moment of inclusion).

3 222 Marsman et al Figure 2. Flow chart showing the main routes of health care for patients with rheumatoid arthritis and foot symptoms in a secondary care center in The Netherlands. for all patients at disease onset; however, subsequent data were only available for patients with a longer followup period. Patients who relocated (n 67) or died (n 57) were considered lost to followup. Procedures. In a secondary care center in The Netherlands, rheumatologists can refer RA patients with foot symptoms to a variety of specialists, including podiatrists, rehabilitation physicians, and orthopedic surgeons (Figure 2). The latter 2 specialists can refer patients to the podiatrist or to the multidisciplinary foot-care clinic. The multidisciplinary foot-care clinic is a collaboration between a rehabilitation physician and an orthopedic shoemaker. In the majority of cases, referrals result in one of the following interventions: the provision of foot orthoses in nonprescription shoes, therapeutic footwear, or orthopedic surgery (Figure 2). Measures. Demographic and clinical characteristics. Demographic data, general disease-related factors, and foot-related factors were recorded in the EAC. The demographic data used in the present study were sex and age. The general disease-related factors at baseline included the Disease Activity Score in 28 joints (DAS28) (16), the percentage of patients who tested positive for IgM rheumatoid factor, symptom duration, the total Sharp/van der Heijde score (SHS), and the total score of the Health Assessment Questionnaire (HAQ) (17). The walking disability subscale of the HAQ was reported separately. The foot-related factors at baseline included erosion and joint space narrowing of the MTP and interphalangeal joints (using the SHS) (18), pain by palpation of the MTP joints, and the presence or absence of swelling of the MTP joints. Foot-related health care use. All visits to the podiatrist, rehabilitation physician, orthopedic surgeon, and the multidisciplinary foot-care clinic were registered in the Reade registration system. Whether a visit to the rehabilitation physician or orthopedic surgeon was (partially) related to foot symptoms and the type of intervention prescribed during such a visit was independently registered by 3 researchers (AFM and RD or AFM and LDR) using the patient s medical records and a standard case record form. Consensus regarding whether a visit concerned foot symptoms and the intervention prescribed was high between the researchers. Consensus on these issues was immediately reached in 85.1% and 81.5% of rehabilitation physician consultations and orthopedic surgeon consultations, respectively. In the remaining cases, consensus was reached after discussion. Statistical analysis. For the demographic and clinical characteristics, means and SDs were calculated for age and DAS28 score, while medians and interquartile ranges (IQRs) were calculated for the remaining patient characteristics at baseline. Regarding the prevalence of painful and swollen MTP joints, forefoot joint damage, and walking disability, percentages were calculated using a cutoff score of 1 for all variables. Additionally, t- tests, Mann-Whitney tests, and Pearson s chi-square tests were performed to compare baseline characteristics of patients with full followup (n 963) against those who were lost to followup (n 124). Two-sided testing was used, and P values less than 0.05 were considered significant. For foot-related health care, secondary care health care use during the disease process was visualized in graphs per year of followup. To analyze the course of health care use, logistic regression analyses for longitudinal data were performed using generalized estimating equation analyses, corrected for the duration of followup. The patients were divided into 11 cohorts based on the year of inclusion. The eleventh cohort contained all patients included between 2005 and 2010 because of the scarcity of data for each year in this period. We subsequently investigated whether the association between health care use and the disease process was linear, quadratic, or cubic. Pearson s chi-square test was performed on health care use per discipline, in order to ascertain any correlations between disciplines. A P value of less than 0.05 was considered significant. All analyses were performed using SPSS, version 17.0.

4 RA and Foot-Related Health Care Use 223 Table 1. Patient characteristics at baseline* Variable Value No. of patients evaluated Women, % ,087 Age, mean SD years ,086 Duration of symptoms, median (IQR) months 4.2 ( ) 1,057 Rheumatoid factor positive, % ,038 Painful and swollen joints according to DAS28, mean SD ,080 Painful MTP joints ( 1 joint), % ,087 No. of painful MTP joints, median (IQR) 3.0 ( ) 1,087 Swollen MTP joints ( 1 joint), % ,087 No. of swollen MTP joints, median (IQR) 3.0 ( ) 1,087 SHS total score, median (IQR) 0 ( ) 790 Erosion score feet ( 1 joint), % Erosion score feet, median (IQR) 0.0 ( ) 806 Joint space narrowing feet ( 1 joint), % Joint space narrowing score feet, median (IQR) 0.0 ( ) 806 SHS feet, median (IQR) 0.0 ( ) 806 HAQ DI total score, median (IQR) 1.3 ( ) 1,062 HAQ DI walking subscale (score 1), % ,061 HAQ DI walking subscale, median (IQR) 0.0 ( ) 1,061 * IQR interquartile range; DAS28 Disease Activity Score in 28 joints; MTP metatarsophalangeal; SHS Sharp/van der Heijde; HAQ Health Assessment Questionnaire; DI disability index. Reduced numbers in the SHS are due to a delay in the scoring of radiographs. RESULTS Patient characteristics. The baseline characteristics of the patients are shown in Table 1. There were differences between the patients with full followup (n 963) and the patients lost to followup (n 124; data not shown). The group of patients lost to followup had a lower percentage of women (58.9% versus 72.0%; P 0.003), was older (59.9 versus 53.7 years; P 0.001), and had a higher DAS28 score (5.6 versus 5.1; P 0.001) compared to patients with full followup. Health care use. Podiatrist. A total of 357 patients (32.9%) visited the podiatrist in secondary care during the course of their disease. The median time between diagnosis and the initial visit to the podiatrist was 1.0 year (IQR years). A total of 13 patients were referred to the podiatrist by the rehabilitation physician and orthopedic surgeon. The remaining patients were directly referred by their rheumatologist. The prevalence of visits to the podiatrist was highest in the first 2 years after diagnosis (Figure 3A). A significant linear decrease in visits to the podiatrist of 6.0% per year was shown by the logistic regression analyses (P 0.002) (Figure 4A). The differences between the cohorts were negligible. Rehabilitation physician. A total of 323 patients (29.8%) visited the rehabilitation physician during the course of their disease, 97 (30.0%) of which had foot symptoms. The Figure 3. Percentage and confidence interval of patients visiting the podiatrist (A), the rehabilitation physician (B), the orthopedic surgeon (C), and the multidisciplinary foot-care clinic (D) during the course of the disease.

5 224 Marsman et al Figure 4. Model-based proportion of patients visiting the podiatrist (A), the rehabilitation physician (B), the orthopedic surgeon (C), and the multidisciplinary foot-care clinic (D) during the course of the disease. median time between diagnosis and the first foot-related visit was 3.0 years (IQR years). Among these 97 patients, an increase in visits over time was observed, with a peak prevalence occurring between year 10 and 11 of the disease. This peak was followed by a subsequent decrease in visits, with a second peak occurring at 14 years of followup (n 37) (Figure 3B). This line was confirmed using logistic regression analyses, which showed a significant quadratic association between visits to the rehabilitation physician and time (P 0.045) (Figure 4B). The observed differences between the cohorts were negligible. The rehabilitation physician referred 95 patients (97.9% of the foot-related visits) for an intervention. Among these patients, 68 were referred to 1 specialist and 27 to 2 specialists, resulting in a total of 129 referrals. Patients who were referred to 2 specialists were mainly referred to the multidisciplinary foot-care clinic in combination with diagnostic procedures. Eleven patients were referred to the podiatrist after a median time of 2.0 years (IQR years) following diagnosis and 5 patients received foot orthoses during the course of their disease. Four patients were referred to the orthopedic surgeon after a median time of 6.5 years (IQR years) following diagnosis. A total of 73 patients were referred to the multidisciplinary foot-care clinic to be supplied with therapeutic footwear after a median time of 3.0 years ( years) following diagnosis. Four patients were referred for adjustments to their conventional shoes. A total of 32 patients were referred after a median time of 4.0 years (IQR years) for other, mainly diagnostic procedures following the initial diagnosis. Orthopedic surgeon. A total of 150 patients (13.8%) visited the orthopedic surgeon in the course of their disease, of which 57 (38.0%) had foot symptoms. The median time between diagnosis and the first foot-related visit was 3 years (IQR years). Among these 57 patients, a minority of patients visited the orthopedic surgeon during the first year of their disease (Figure 3C). Logistic regression analyses showed a significant increase in visits of 9.0% per year (P 0.010) (Figure 4C). The observed differences between the cohorts were negligible. The orthopedic surgeon referred 56 patients (98.2% of the foot-related visits) for an intervention. Among these patients, 30 were referred to 1 specialist and 26 to 2 specialists, resulting in a total of 100 referrals. Patients who were referred to 2 specialists were mainly referred to the orthopedic surgeon in combination with diagnostic procedures. Two patients were referred to the podiatrist after a median time of 5.0 years (IQR years) following diagnosis and 9 patients received foot orthoses. Thirty-two patients underwent orthopedic surgery after a median time of 4.0 years (IQR years) following the initial diagnosis. A total of 13 patients were referred to the multidisciplinary foot-care clinic after a median time of 4.0 years (IQR years) following diagnosis, and in a majority of the cases, this was to supply the patients with therapeutic footwear. Five patients were referred for adjustments to their conventional shoes. A total of 39 patients were referred for other, mainly diagnostic procedures after a median time of 3.0 years (IQR years) following diagnosis. Multidisciplinary foot-care clinic. A total of 86 patients were referred by the rehabilitation physician and the orthopedic surgeon to the multidisciplinary foot-care clinic to be supplied with therapeutic footwear. Ultimately, a total of 81 patients (7.5%) visited the multidisciplinary foot-care clinic. The median time between diagnosis and the first visit to the multidisciplinary foot-care clinic was 3.0 years (IQR years). During the first 3 years after diagnosis, a minority of patients visited the multidisci-

6 RA and Foot-Related Health Care Use 225 plinary foot-care clinic. This slightly increased to reach a stable level between years 4 and 10 after diagnosis (Figure 3D). This line was confirmed using logistic regression analyses, which showed a significant and cubic association between visits to the multidisciplinary foot-care clinic and time (P 0.035) (Figure 4D). The observed differences between cohorts were negligible. Pearson s chi-square test showed a significant association between visits to the rehabilitation physician and to the multidisciplinary foot-care clinic each year up to a maximum of 15 years of followup. The patients visiting the multidisciplinary foot-care clinic were likely to have been referred by the rehabilitation physician. DISCUSSION This study investigated specialist-provided foot-related health care usage in patients with RA, with a maximum of 15 years of followup. The present study took place in a secondary care center, with health care professionals within one center focusing on foot symptoms, which made it more likely for patients to be referred to other foot-related specialists. The prevalence of visits reported in this study might therefore be an overestimation when compared to visits of patients not treated in a secondary care institution specializing in rheumatology and rehabilitation. The patients with foot symptoms were most likely to be seen by the podiatrist, who was visited by 32.9% of patients during the course of their disease. In particular, patients with foot symptoms developing early in the disease process were referred to the podiatrist by the rheumatologist. This is evident, given that 15% of patients visited the podiatrist in the first year after diagnosis. This can be explained by the easily accessible and noninvasive nature of podiatry, mainly consisting of foot and/or toe orthoses and additional shoe-related advice. The results of another recent study from our research group showed that podiatric treatment in the early phase of the disease resulted in better outcomes regarding pain and disability than podiatric treatment later in the disease process, when irreversible joint damage and deformities could have developed (19). In the present study, a minority of patients visited the rehabilitation physician, the orthopedic surgeon, and the multidisciplinary foot-care clinic during the first 2 years following diagnosis, with an increase in the years that followed. When podiatry was not sufficient because of worsening of the foot symptoms (e.g., due to erosions and structural deformities), the rheumatologist subsequently referred patients to the rehabilitation physician after a median time of 3 years. The rheumatologist and the rehabilitation physician have different roles in The Netherlands; the rheumatologist is primarily responsible for the pharmacologic management, while the rehabilitation physician is responsible for the nonpharmacologic conservative management. In general, conservative management consists of multidisciplinary treatment. In the present study, the rehabilitation physician made the most of his or her referrals to the multidisciplinary foot-care clinic, which is a close collaboration between the rehabilitation physician and an orthopedic shoemaker. The main focus of the multidisciplinary foot-care clinic was providing therapeutic footwear to the patients. After a median of 4 years, the orthopedic surgeon was the final step in the management of foot symptoms, with surgical correction of the damaged foot being the main focus of the orthopedic surgeon. The main advantage of this study is the longitudinal study design. Previously conducted studies, such as the study by Boonen et al, investigated foot symptoms in a cross-sectional design, which gave no insight into health care use throughout the disease process (13). The number of patients (n 1,087) and long followup duration (15 years) of this study made it possible to review foot-related health care use during the course of RA. Due to the absence of comparable studies, it is impossible to discuss the results found in this study in reference to other studies. The limitations of this study mainly concern the type of prescribed interventions. The present data show whether a patient received podiatric treatment or surgery, but information regarding the specific type of orthoses supplied to patients or the exact surgical procedures undertaken is lacking. Furthermore, antirheumatic drugs influence the disease course and might subsequently influence the development and severity of foot symptoms and, therefore, the use of foot-related health care. Treatment strategies have evolved throughout time and great innovations have been made by the emergence of anti tumor necrosis factor therapies. Since information about the use of medication is not consistently registered in the EAC, the influence of these new therapies on foot-related health care use is not known. Finally, in the Dutch health care system, patients can also be referred directly to a primary care podiatrist by their primary care physician. Moreover, some patients preferred to receive podiatry by a primary care podiatrist outside the center. These routes were not included in the present study, which took place in a secondary care center. So, although the majority of patients would be expected to have received foot-related care in our outpatient clinic, the reported percentages concerning podiatry might be an underestimation. Also, basic podiatric care, such as callus debridement and nail cutting, was not included in this study. In view of the high prevalence of painful and swollen MTP joints early in the RA disease process ( 70% of patients have painful or swollen MTP joints at diagnosis) (2), the question arises as to whether there is an underuse of care for foot symptoms, most likely being reported as pain during weight-bearing activities, such as standing, walking, and running. Woodburn et al describe a window of opportunity in the early phases of RA, consisting of the early detection of foot problems, targeted therapy, tight control of foot arthritis, and disease monitoring (20). It might be assumed that early podiatry intervention prevents further pain, loss of foot function, and loss of physical functioning, although there is limited evidence to support this assumption (21). The present study points out the possibility of an underuse of care, which is an important target for future research. Further development of preventive health care strategies and integrated foot care

7 226 Marsman et al (e.g., standard referral of newly diagnosed RA patients to the podiatrist) are possible strategies for the prevention of the underuse of care (20). In conclusion, RA patients with foot symptoms visited the podiatrist at an early stage in the disease process. When foot symptoms worsened, patients visited the rehabilitation physician, who subsequently referred patients to the multidisciplinary foot-care clinic for therapeutic footwear. The orthopedic surgeon was the final step in the management of foot symptoms. AUTHOR CONTRIBUTIONS All authors were involved in drafting the article or revising it critically for important intellectual content, and all authors approved the final version to be published. Dr. van der Leeden had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. Study conception and design. Marsman, Dahmen, Roorda, van der Leeden. Acquisition of data. Marsman, Dahmen, Roorda, van Schaardenburg, Britsemmer, van der Leeden. Analysis and interpretation of data. Marsman, Dahmen, Roorda, Dekker, Knol, van der Leeden. REFERENCES 1. Michelson J, Easley M, Wigley FM, Hellmann D. Foot and ankle problems in rheumatoid arthritis. Foot Ankle Int 1994; 15: Van der Leeden M, Steultjens MP, Ursum J, Dahmen R, Roorda LD, van Schaardenburg D, et al. Prevalence and course of forefoot impairments and walking disability in the first eight years of rheumatoid arthritis. Arthritis Rheum 2008;59: Van de Stadt LA, Bos WH, Meursinge Reynders M, Wieringa H, Turkstra F, van der Laken CJ, et al. The value of ultrasonography in predicting arthritis in auto-antibody positive arthralgia patients: a prospective cohort study. Arthritis Res Ther 2010;12:R Van der Leeden M, Steultjens M, Dekker JH, Prins AP, Dekker J. Forefoot joint damage, pain and disability in rheumatoid arthritis patients with foot complaints: the role of plantar pressure and gait characteristics. Rheumatology (Oxford) 2006;45: Grondal L, Tengstrand B, Nordmark B, Wretenberg P, Stark A. The foot: still the most important reason for walking incapacity in rheumatoid arthritis. Distribution of symptomatic joints in 1,000 RA patients. Acta Orthop 2008;79: Wickman AM, Pinzur MS, Kadanoff R, Juknelis D. Healthrelated quality of life for patients with rheumatoid arthritis foot involvement. Foot Ankle Int 2004;25: Baan H, Drossaers-Bakker W, Dubbeldam R, van de Laar M. We should not forget the foot: relations between signs and symptoms, damage, and function in rheumatoid arthritis. Clin Rheumatol 2011;30: Combe B, Landewe R, Lukas C, Bolosiu HD, Breedveld F, Dougados M, et al. EULAR recommendations for the management of early arthritis: report of a task force of the European Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 2007;66: Jeng C, Campbell J. Current concepts review: the rheumatoid forefoot. Foot Ankle Int 2008;29: Clark H, Rome K, Plant M, O Hare K, Gray J. A critical review of foot orthoses in the rheumatoid arthritic foot. Rheumatology (Oxford) 2006;45: Egan M, Brosseau L, Farmer M, Ouimet MA, Rees S, Wells G, et al. Splints/orthoses in the treatment of rheumatoid arthritis. Cochrane Database Syst Rev 2003;1:CD Matricali GA, Boonen A, Verduyckt J, Taelman V, Verschueren P, Sileghem A, et al. The presence of forefoot problems and the role of surgery in patients with rheumatoid arthritis. Ann Rheum Dis 2006;65: Boonen A, Matricali GA, Verduyckt J, Taelman V, Verschueren P, Sileghem A, et al. Orthopaedic surgery in patients with rheumatoid arthritis: a shift towards more frequent and earlier non-joint-sacrificing surgery. Ann Rheum Dis 2006;65: Jansen LM, van Schaardenburg D, van der Horst-Bruinsma IE, Bezemer PD, Dijkmans BA. Predictors of functional status in patients with early rheumatoid arthritis. Ann Rheum Dis 2000;59: Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31: Prevoo ML, van t Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL. Modified disease activity scores that include twenty-eight joint counts: development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995;38: Bijlsma J, Oude Heuvel C, Zaalberg A. Development and validation of the Dutch questionnaire Capacities of Daily Life (VDF) for patients with rheumatoid arthritis. J Rehabil Sci 1990;3: Van der Heijde DM. How to read radiographs according to the Sharp/van der Heijde method. J Rheumatol 1999;26: Van der Leeden M, Fiedler K, Jonkman A, Dahmen R, Roorda LD, van Schaardenburg D, et al. Factors predicting the outcome of customised foot orthoses in patients with rheumatoid arthritis: a prospective cohort study. J Foot Ankle Res 2011; 4: Woodburn J, Hennessy K, Steultjens MP, McInnes IB, Turner DE. Looking through the window of opportunity : is there a new paradigm of podiatry care on the horizon in early rheumatoid arthritis? J Foot Ankle Res 2010;3: Budiman-Mak E, Conrad KJ, Roach KE, Moore JW, Lertratanakul Y, Koch AE, et al. Can foot orthoses prevent hallux valgus deformity in rheumatoid arthritis? A randomized clinical trial. J Clin Rheumatol 1995;1:

We should not forget the foot: relations between signs and symptoms, damage, and function in rheumatoid arthritis

We should not forget the foot: relations between signs and symptoms, damage, and function in rheumatoid arthritis Clin Rheumatol (2011) 30:1475 1479 DOI 10.1007/s10067-011-1780-8 ORIGINAL ARTICLE We should not forget the foot: relations between signs and symptoms, damage, and function in rheumatoid arthritis Henriëtte

More information

British Journal of Rheumatology 1996;35:1101-1105

British Journal of Rheumatology 1996;35:1101-1105 British Journal of Rheumatology 1996;35:1101-1105 REMISSION IN A PROSPECTIVE STUDY OF PATIENTS WITH RHEUMATOID ARTHRITIS. AMERICAN RHEUMATISM ASSOCIATION PRELIMINARY REMISSION CRITERIA IN RELATION TO THE

More information

PREVALENCE OF HAND SYMPTOMS, IMPAIRMENTS AND ACTIVITY LIMITATIONS IN RHEUMATOID ARTHRITIS IN RELATION TO DISEASE

PREVALENCE OF HAND SYMPTOMS, IMPAIRMENTS AND ACTIVITY LIMITATIONS IN RHEUMATOID ARTHRITIS IN RELATION TO DISEASE J Rehabil Med 1; : 91 91 ORIGINAL REPORT PREVALENCE OF HAND SYMPTOMS, IMPAIRMENTS AND ACTIVITY LIMITATIONS IN RHEUMATOID ARTHRITIS IN RELATION TO DISEASE DURATION Noortje C. A. Horsten, MD 1, Jennie Ursum,

More information

Changes in foot function, disease activity, and disability after forefoot resection arthroplasty in patients with rheumatoid arthritis

Changes in foot function, disease activity, and disability after forefoot resection arthroplasty in patients with rheumatoid arthritis Changes in foot function, disease activity, and disability after forefoot resection arthroplasty in patients with rheumatoid arthritis Fusakazu Sawachika 1,2, Hirokazu Uemura 1, Sakurako Katsuura-Kamano

More information

Dr Sarah Levy Consultant Rheumatology Croydon University Hospital

Dr Sarah Levy Consultant Rheumatology Croydon University Hospital Dr Sarah Levy Consultant Rheumatology Croydon University Hospital Contents Definition/ epidemiology Diagnosis Importance of early diagnosis/ treatment Guidelines Evidence based treatment protocol Current

More information

DISEASE COURSE IN EARLY RHEUMATOID ARTHRITIS: AN OBSERVATIONAL STUDY

DISEASE COURSE IN EARLY RHEUMATOID ARTHRITIS: AN OBSERVATIONAL STUDY ORIGINAL ARTICLES DISEASE COURSE IN EARLY RHEUMATOID ARTHRITIS: AN OBSERVATIONAL STUDY Teodora Serban 1,2, Iulia Satulu 2, Oana Vutcanu 2, Mihaela Milicescu 1,2, Carina Mihai 1,2, Mihai Bojinca 1,2, Victor

More information

Early identification and treatment - the Norwegian perspective. Till Uhlig Dept of Rheumatology Diakonhjemmet Hospital Oslo, Norway

Early identification and treatment - the Norwegian perspective. Till Uhlig Dept of Rheumatology Diakonhjemmet Hospital Oslo, Norway Early identification and treatment - the Norwegian perspective Till Uhlig Dept of Rheumatology Diakonhjemmet Hospital Oslo, Norway Oslo Rheumatoid Arthritis Registry (ORAR) Very early Arthritis Clinic

More information

The Widening Mortality Gap Between Rheumatoid Arthritis Patients and the General Population

The Widening Mortality Gap Between Rheumatoid Arthritis Patients and the General Population ARTHRITIS & RHEUMATISM Vol. 56, No. 11, November 2007, pp 3583 3587 DOI 10.1002/art.22979 2007, American College of Rheumatology The Widening Mortality Gap Between Rheumatoid Arthritis Patients and the

More information

Bone Erosions in Patients with RA: Exploring the Impact of the Anatomy of Interest on the Relationship Between MRI and X-ray Erosion Detection

Bone Erosions in Patients with RA: Exploring the Impact of the Anatomy of Interest on the Relationship Between MRI and X-ray Erosion Detection Bone Erosions in Patients with RA: Exploring the Impact of the Anatomy of Interest on the Relationship Between MRI and X-ray Erosion Detection Michael Tomizza, BSc, MSc Candidate October 15, 2014: Hamilton

More information

Treating Rheumatoid Arthritis to Target : the patient version of the international recommendations

Treating Rheumatoid Arthritis to Target : the patient version of the international recommendations Treating Rheumatoid Arthritis to Target : the patient version of the international recommendations Data presented from the publication: M. de Wit, et al. Ann Rheum Dis. 2011;70:891-5. Epub Apr 7, 2011.

More information

Predictors of Physical Therapy Use in Patients with Rheumatoid Arthritis

Predictors of Physical Therapy Use in Patients with Rheumatoid Arthritis Predictors of Physical Therapy Use in Patients with Rheumatoid Arthritis Maura Iversen,, PT, DPT, SD, MPH 1,2,3 Ritu Chhabriya,, MSPT 4 Nancy Shadick, MD 2,3 1 Department of Physical Therapy, Northeastern

More information

Treat to Target Approach in Rheumatoid Arthritis: UK perspective. Dr Deirdre Shawe, North Hampshire Hospital, Basingstoke, UK

Treat to Target Approach in Rheumatoid Arthritis: UK perspective. Dr Deirdre Shawe, North Hampshire Hospital, Basingstoke, UK Treat to Target Approach in Rheumatoid Arthritis: UK perspective Dr Deirdre Shawe, North Hampshire Hospital, Basingstoke, UK What is the target? To achieve remission or low disease activity in Rheumatoid

More information

Treatment of Recalcitrant Intermetatarsal Neuroma With 4% Sclerosing Alcohol Injection: A Pilot Study

Treatment of Recalcitrant Intermetatarsal Neuroma With 4% Sclerosing Alcohol Injection: A Pilot Study Treatment of Recalcitrant Intermetatarsal Neuroma With 4% Sclerosing Alcohol Injection: A Pilot Study Christopher F. Hyer, DPM,' Lynette R. Mehl, DPM,2 Alan J. Block, DPM, MS, FACFAS,3 and Robert B. Vancourt,

More information

Effectiveness and Drug Adherence in Rheumatoid Arthritis Patients on Biologic Monotherapy: A prospective observational study in Southern Sweden

Effectiveness and Drug Adherence in Rheumatoid Arthritis Patients on Biologic Monotherapy: A prospective observational study in Southern Sweden Effectiveness and Drug Adherence in Rheumatoid Arthritis Patients on Biologic Monotherapy: A prospective observational study in Southern Sweden Collaborators: Primary investigators Dr Lars Erik Kristensen,

More information

Understanding and improving communications between people with rheumatoid arthritis and their healthcare professionals. RCUKCOMM00116w February 2014

Understanding and improving communications between people with rheumatoid arthritis and their healthcare professionals. RCUKCOMM00116w February 2014 Understanding and improving communications between people with rheumatoid arthritis and their healthcare professionals RCUKCOMM00116w February 2014 This project has been funded by Roche Products Ltd &

More information

Disease Activity and Disability in Women and Men With Early Rheumatoid Arthritis (RA): An 8-Year Followup of a Swedish Early RA Project

Disease Activity and Disability in Women and Men With Early Rheumatoid Arthritis (RA): An 8-Year Followup of a Swedish Early RA Project Arthritis Care & Research Vol. 64, No. 8, August 2012, pp 1101 1107 DOI 10.1002/acr.21662 2012, American College of Rheumatology ORIGINAL ARTICLE Disease Activity and Disability in Women and Men With Early

More information

Foot Problems in a Group of Patients with Rheumatoid Arthritis: An Unmet Need for Foot Care

Foot Problems in a Group of Patients with Rheumatoid Arthritis: An Unmet Need for Foot Care Send Orders of Reprints at reprints@benthamscience.org 290 The Open Rheumatology Journal, 2012, 6, 290-295 Open Access Foot Problems in a Group of Patients with Rheumatoid Arthritis: An Unmet Need for

More information

Understanding Rheumatoid Arthritis

Understanding Rheumatoid Arthritis Understanding Rheumatoid Arthritis Understanding Rheumatoid Arthritis What Is Rheumatoid Arthritis? 1,2 Rheumatoid arthritis (RA) is a chronic autoimmune disease. It causes joints to swell and can result

More information

Rheumatology Advance Access published February 1, 2012

Rheumatology Advance Access published February 1, 2012 Rheumatology Advance Access published February 1, 2012 RHEUMATOLOGY Concise report doi:10.1093/rheumatology/ker425 The provisional ACR/EULAR definition of remission in RA: a comment on the patient global

More information

1.0 Abstract. Title: Real Life Evaluation of Rheumatoid Arthritis in Canadians taking HUMIRA. Keywords. Rationale and Background:

1.0 Abstract. Title: Real Life Evaluation of Rheumatoid Arthritis in Canadians taking HUMIRA. Keywords. Rationale and Background: 1.0 Abstract Title: Real Life Evaluation of Rheumatoid Arthritis in Canadians taking HUMIRA Keywords Rationale and Background: This abbreviated clinical study report is based on a clinical surveillance

More information

Anti Carbamylated Protein Antibodies (Anti- CarP) are Present in Arthralgia Patients and Predict the Development of Rheumatoid Arthritis

Anti Carbamylated Protein Antibodies (Anti- CarP) are Present in Arthralgia Patients and Predict the Development of Rheumatoid Arthritis Anti Carbamylated Protein Antibodies (Anti- CarP) are Present in Arthralgia Patients and Predict the Development of Rheumatoid Arthritis Jing Shi 1 * Lotte A. van de Stadt 2 * E.W. Nivine Levarht 1 Tom

More information

Development of Antiinfliximab Antibodies and Relationship to Clinical Response in Patients With Rheumatoid Arthritis

Development of Antiinfliximab Antibodies and Relationship to Clinical Response in Patients With Rheumatoid Arthritis ARTHRITIS & RHEUMATISM Vol. 54, No. 3, March 2006, pp 711 715 DOI 10.1002/art.21671 2006, American College of Rheumatology Development of Antiinfliximab Antibodies and Relationship to Clinical Response

More information

Etanercept (Enbrel ) in Patients with Rheumatoid Arthritis with Recent Onset Versus Established Disease: Improvement in Disability

Etanercept (Enbrel ) in Patients with Rheumatoid Arthritis with Recent Onset Versus Established Disease: Improvement in Disability Etanercept (Enbrel ) in Patients with Rheumatoid Arthritis with Recent Onset Versus Established Disease: Improvement in Disability SCOTT W. BAUMGARTNER, ROY M. FLEISCHMANN, LARRY W. MORELAND, MICHAEL H.

More information

Rheumatoid Arthritis and Treat-to-Target

Rheumatoid Arthritis and Treat-to-Target Rheumatoid Arthritis and Treat-to-Target A Case of Need Encountering Opportunity Need RA affects approximately 1.5 million adults in the United States 1 20%-30% face permanent work disability if not treated

More information

Comparison of treatment outcome in Rheumatoid Arthritis patients treated with single and two DMARDs in combination with Corticosteroids

Comparison of treatment outcome in Rheumatoid Arthritis patients treated with single and two DMARDs in combination with Corticosteroids International Journal of Drug Development & Research July-September 2012 Vol. 4 Issue 3 ISSN 0975-9344 Available online http://www.ijddr.in Covered in Official Product of Elsevier, The Netherlands SJR

More information

A pilot study of the primary care management of knee osteoarthritis in the Northern States of Malaysia.

A pilot study of the primary care management of knee osteoarthritis in the Northern States of Malaysia. A pilot study of the primary care management of knee osteoarthritis in the Northern States of Malaysia. Arshad A and Rashid R Putra Specialist Centre, Alor Setar, Kedah, Malaysia ABSTRACT ORIGINAL ARTICLE

More information

Very early rheumatoid arthritis as a predictor of remission: a multicentre real life prospective study

Very early rheumatoid arthritis as a predictor of remission: a multicentre real life prospective study EXTENDED REPORT Very early rheumatoid arthritis as a predictor of remission: a multicentre real life prospective study Elisa Gremese, 1 Fausto Salaffi, 2 Silvia Laura Bosello, 1 Alessandro Ciapetti, 2

More information

COMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP)

COMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP) The European Agency for the Evaluation of Medicinal Products Evaluation of Medicines for Human Use London, 17 December 2003 CPMP/EWP/556/95 rev 1/Final COMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP)

More information

Rheumatoid Arthritis: Symptoms, Causes, and Treatments of Rheumatoid Foot and Ankle

Rheumatoid Arthritis: Symptoms, Causes, and Treatments of Rheumatoid Foot and Ankle Rheumatoid arthritis is the most common form of inflammatory arthritis, affecting about two to three million Americans. Rheumatoid arthritis is a symmetric disease, meaning that it will usually involve

More information

(Intro to Arthritis with a. Arthritis) Manager of Education & Services for the Vancouver Island Region of The Arthritis Society

(Intro to Arthritis with a. Arthritis) Manager of Education & Services for the Vancouver Island Region of The Arthritis Society Arthritis 101 (Intro to Arthritis with a Focus on Rheumatoid Arthritis) by Cari Taylor by Cari Taylor Manager of Education & Services for the Vancouver Island Region of The Arthritis Society What You Will

More information

Evolution of Classification Criteria for Rheumatoid Arthritis: How Do the 2010 Criteria Perform?

Evolution of Classification Criteria for Rheumatoid Arthritis: How Do the 2010 Criteria Perform? Evolution of Classification Criteria for Rheumatoid Arthritis: How Do the 2010 Criteria Perform? Elizabeth C. Ortiz, MD*, Shuntaro Shinada, MD KEYWORDS Rheumatoid arthritis Classification criteria Inflammatory

More information

ABOUT RHEUMATOID ARTHRITIS

ABOUT RHEUMATOID ARTHRITIS MEDIA BACKGROUNDER ABOUT RHEUMATOID ARTHRITIS Rheumatoid arthritis (RA) is a type of arthritis (chronic inflammatory polyarthritis) that typically affects hands and feet, although any joint in the body

More information

SYNOPSIS. 2-Year (0.5 DB + 1.5 OL) Addendum to Clinical Study Report

SYNOPSIS. 2-Year (0.5 DB + 1.5 OL) Addendum to Clinical Study Report Name of Sponsor/Company: Bristol-Myers Squibb Name of Finished Product: Abatacept () Name of Active Ingredient: Abatacept () Individual Study Table Referring to the Dossier (For National Authority Use

More information

Immune modulation in rheumatology. Geoff McColl University of Melbourne/Australian Rheumatology Association

Immune modulation in rheumatology. Geoff McColl University of Melbourne/Australian Rheumatology Association Immune modulation in rheumatology Geoff McColl University of Melbourne/Australian Rheumatology Association A traditional start to a presentation on biological agents in rheumatic disease is Plasma cell

More information

Implementation of a Treat-to-Target Strategy in Very Early Rheumatoid Arthritis

Implementation of a Treat-to-Target Strategy in Very Early Rheumatoid Arthritis ARTHRITIS & RHEUMATISM Vol. 63, No. 10, October 2011, pp 2865 2872 DOI 10.1002/art.30494 2011, American College of Rheumatology Implementation of a Treat-to-Target Strategy in Very Early Rheumatoid Arthritis

More information

Long-Term Impact of Delay in Assessment of Patients With Early Arthritis

Long-Term Impact of Delay in Assessment of Patients With Early Arthritis ARTHRITIS & RHEUMATISM Vol. 62, No. 12, December 2010, pp 3537 3546 DOI 10.1002/art.27692 2010, American College of Rheumatology Long-Term Impact of Delay in Assessment of Patients With Early Arthritis

More information

Predislocation syndrome

Predislocation syndrome Predislocation syndrome Sky Ridge Medical Center, Aspen Building Pre-dislocation syndrome, capsulitis, and metatarsalgia are all similar problems usually at the ball of the foot near the second and third

More information

2010 ACR/EULAR Classification Criteria for Rheumatoid Arthritis

2010 ACR/EULAR Classification Criteria for Rheumatoid Arthritis 2010 ACR/EULAR Classification Criteria for Rheumatoid Arthritis Published in the September 2010 Issues of A&Rand ARD Phases of the Project Phase 1 Data analysis Phase 2 Consensus process Predictors of

More information

Vectra DA Blood Test for Rheumatoid Arthritis. Original Policy Date January /2014

Vectra DA Blood Test for Rheumatoid Arthritis. Original Policy Date January /2014 MP 2.04.81 Vectra DA Blood Test for Rheumatoid Arthritis Medical Policy Section 2.0 Original Policy Date January /2014 Last Review Status/Date 1/2014 Disclaimer Our medical policies are designed for informational

More information

Treating Rheumatoid Arthritis to Target : multinational recommendations assessment

Treating Rheumatoid Arthritis to Target : multinational recommendations assessment Treating Rheumatoid Arthritis to Target : multinational recommendations assessment The results of the physicians survey Data presented from the publication: B. Haraoui, et al. Ann Rheum Dis. 2011;70:1999-2002.

More information

Early Diagnosis of Rheumatoid Arthritis & Axial Spondyloarthritis

Early Diagnosis of Rheumatoid Arthritis & Axial Spondyloarthritis Early Diagnosis of Rheumatoid Arthritis & Axial Spondyloarthritis 奇 美 醫 院 過 敏 免 疫 風 濕 科 陳 宏 安 Rheumatoid arthritis Most common chronic inflammatory joint disease Multisystem autoimmune disease of unknown

More information

Favorable Effect of Very Early Disease-Modifying Antirheumatic Drug Treatment on Radiographic Progression in Early Inflammatory Arthritis

Favorable Effect of Very Early Disease-Modifying Antirheumatic Drug Treatment on Radiographic Progression in Early Inflammatory Arthritis ARTHRITIS & RHEUMATISM Vol. 63, No. 7, July 2011, pp 1804 1811 DOI 10.1002/art.30371 2011, American College of Rheumatology Favorable Effect of Very Early Disease-Modifying Antirheumatic Drug Treatment

More information

Physical Therapy Self-Referral ( Direct Access )

Physical Therapy Self-Referral ( Direct Access ) Physical Therapy Self-Referral ( Direct Access ) Summary of Statutes and Regulations by State December 2007 The American Association of Orthopaedic Surgeons (AAOS) supports a patient-centered approach

More information

Current Rheumatoid Arthritis Treatment Options: Update for Managed Care and Specialty Pharmacists

Current Rheumatoid Arthritis Treatment Options: Update for Managed Care and Specialty Pharmacists Current Rheumatoid Arthritis Treatment Options: Update for Managed Care and Specialty Pharmacists 1. Which of the following matches of biologic targets that contribute to rheumatoid arthritis (RA) and

More information

Disease Therapy Management (DTM) Enhances Rheumatoid Arthritis Treatment

Disease Therapy Management (DTM) Enhances Rheumatoid Arthritis Treatment A WHITE PAPER BY Disease Therapy Management (DTM) Enhances Rheumatoid Arthritis Treatment Increased adherence rates deliver improved outcomes for patients FALL 2010 The Benefits of DTM for Rheumatoid Arthritis

More information

Application of Explicit Process of Care Measurement to Rheumatoid Arthritis: Moving from Evidence to Practice

Application of Explicit Process of Care Measurement to Rheumatoid Arthritis: Moving from Evidence to Practice Arthritis & Rheumatism (Arthritis Care & Research) Vol. 55, No. 6, December 15, 2006, pp 884 891 DOI 10.1002/art.22361 2006, American College of Rheumatology ORIGINAL ARTICLE Application of Explicit Process

More information

Rheumatology Advance Access published January 7, 2013. Autonomous online health assessment questionnaire registry in daily clinical practice

Rheumatology Advance Access published January 7, 2013. Autonomous online health assessment questionnaire registry in daily clinical practice Concise report Rheumatology Advance Access published January 7, 2013 RHEUMATOLOGY 53 doi:10.1093/rheumatology/kes389 Autonomous online health assessment questionnaire registry in daily clinical practice

More information

The Vectra DA Test for Rheumatoid Arthritis

The Vectra DA Test for Rheumatoid Arthritis Medical Policy Manual Topic: Vectra DA Blood Test for Rheumatoid Arthritis Date of Origin: June 2014 Section: Laboratory Last Reviewed Date: May 2015 Policy No: 67 Effective Date: July 1, 2015 IMPORTANT

More information

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE. Health Technology Appraisal

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE. Health Technology Appraisal NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE Health Technology Appraisal Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure

More information

Media Release. Basel, 11 June 2009. RA patients with enhanced response identified

Media Release. Basel, 11 June 2009. RA patients with enhanced response identified Media Release Basel, 11 June 2009 New data demonstrate the ability of MabThera to reduce the progression of joint damage when used as a first-line biologic treatment in rheumatoid arthritis RA patients

More information

Treatment of Severe Rheumatoid Arthritis

Treatment of Severe Rheumatoid Arthritis Treatment of Severe Rheumatoid Arthritis Zhanguo Li Department of Rheumatology and Immunology, People s Hospital Beijing University Medical School, China Contents Background Challenges Treatment strategies

More information

Psoriasis, Incidence, Quality of Life, Psoriatic Arthritis, Prevalence

Psoriasis, Incidence, Quality of Life, Psoriatic Arthritis, Prevalence 1.0 Abstract Title Prevalence and Incidence of Articular Symptoms and Signs Related to Psoriatic Arthritis in Patients with Psoriasis Severe or Moderate with Adalimumab Treatment (TOGETHER). Keywords Psoriasis,

More information

Shared care protocol for the management of patients with Rheumatoid Arthritis treated with disease modifying antirheumatic drugs (DMARDs)

Shared care protocol for the management of patients with Rheumatoid Arthritis treated with disease modifying antirheumatic drugs (DMARDs) Tameside Hospital NHS Foundation Trust and NHS Tameside and Glossop Shared care protocol for the management of patients with Rheumatoid Arthritis treated with disease modifying antirheumatic drugs (DMARDs)

More information

Health Care Needs Assessment of Services for Adults with Rheumatoid Arthritis

Health Care Needs Assessment of Services for Adults with Rheumatoid Arthritis Health Care Needs Assessment of Services for Adults with Rheumatoid Arthritis PART D: Cost Implications for NHS Rheumatoid Arthritis Services in Scotland Scottish Public Health Network August 2013 1 Table

More information

Chapter 4 Physical therapy in rheumatoid arthritis: results of a national survey

Chapter 4 Physical therapy in rheumatoid arthritis: results of a national survey Chapter 4 Physical therapy in rheumatoid arthritis: results of a national survey E.J. Hurkmans L.C. Li J. Verhoef T.P.M. Vliet Vlieland Musckuloskeletal Care [in press] Chapter 4 Abstract Background and

More information

Imaging of Hand in Rheumatoid Arthritis with CR, US and MRI. Azar Bahrami, PGY4 Radiology Rounds Jan, 31, 2007

Imaging of Hand in Rheumatoid Arthritis with CR, US and MRI. Azar Bahrami, PGY4 Radiology Rounds Jan, 31, 2007 Imaging of Hand in Rheumatoid Arthritis with CR, US and MRI Azar Bahrami, PGY4 Radiology Rounds Jan, 31, 2007 Introduction RA most common type of inflammatory Arthritis with prevalence of 1% Accurate and

More information

Rheumatoid Arthritis: Diagnosis, Management and Monitoring

Rheumatoid Arthritis: Diagnosis, Management and Monitoring Rheumatoid Arthritis: Diagnosis, Management and Monitoring Effective Date: September 30, 2012 Scope This guideline is intended to aid in early recognition, intervention and management of patients with

More information

Medical Policy Anti-CCP Testing for Rheumatoid Arthritis

Medical Policy Anti-CCP Testing for Rheumatoid Arthritis Medical Policy Anti-CCP Testing for Rheumatoid Arthritis Table of Contents Policy: Commercial Coding Information Information Pertaining to All Policies Policy: Medicare Description References Authorization

More information

E. de P. Magalhães, M. Davitt 1, D. J. Filho 2, L. R. Battistella 2 and M. B. Be rtolo

E. de P. Magalhães, M. Davitt 1, D. J. Filho 2, L. R. Battistella 2 and M. B. Be rtolo Rheumatology 26;45:449 453 Advance Access publication 15 November 25 The effect of foot orthoses in rheumatoid arthritis E. de P. Magalhães, M. Davitt 1, D. J. Filho 2, L. R. Battistella 2 and M. B. Be

More information

IMPACT OF AGE ON CLINICAL MANIFESTATIONS AND OUTCOME IN PUERTO RICANS

IMPACT OF AGE ON CLINICAL MANIFESTATIONS AND OUTCOME IN PUERTO RICANS IMPACT OF AGE ON CLINICAL MANIFESTATIONS AND OUTCOME IN PUERTO RICANS WITH RHEUMATOID ARTHRITIS Introduction: Disease expression and outcomes in rheumatoid arthritis (RA) vary among different ethnic groups.

More information

Costs and Predictors of Costs in Rheumatoid Arthritis: A Prevalence-Based Study

Costs and Predictors of Costs in Rheumatoid Arthritis: A Prevalence-Based Study Arthritis & Rheumatism (Arthritis Care & Research) Vol. 49, No. 1, February 15, 2003, pp 64 70 DOI 10.1002/art.10905 2003, American College of Rheumatology ORIGINAL ARTICLE Costs and Predictors of Costs

More information

Therapeutic shoes (for individuals with diabetes) and foot (in-shoe) orthotics are reimbursable under Plans administered by QualCare, Inc.

Therapeutic shoes (for individuals with diabetes) and foot (in-shoe) orthotics are reimbursable under Plans administered by QualCare, Inc. Subject: Foot Orthotics and Diabetic Shoes* Effective Date: October 1, 1999 Department(s): Utilization Management Policy: Objective: Procedure: Therapeutic shoes (for individuals with diabetes) and foot

More information

1. Title 2. Background

1. Title 2. Background 1. Title EARLY PsA Effectiveness of early Adalimumab therapy in psoriatic arthritis patients from Reuma.pt, the Rheumatic Diseases Portuguese Register, Portuguese RheumatoLogy SocietY (SPR) 2. Background

More information

DOCTOR DISCUSSION GUIDE FOR RHEUMATOID ARTHRITIS

DOCTOR DISCUSSION GUIDE FOR RHEUMATOID ARTHRITIS DOCTOR DISCUSSION GUIDE FOR RHEUMATOID ARTHRITIS Talking your Doctor About Rheumatoid Arthritis Preparing for your Doctor s Appointment Early and aggressive treatment can help you forestall the joint damage

More information

A User's Guide to: Rheumatoid and Arthritis Outcome Score RAOS

A User's Guide to: Rheumatoid and Arthritis Outcome Score RAOS RAOS User's Guide 2004 A User's Guide to: Rheumatoid and Arthritis Outcome Score RAOS RAOS is developed as an instrument to assess the patients opinion about their hips/knees and/or feet and associated

More information

ACR and EULAR Improvement Criteria Have Comparable Validity in Rheumatoid Arthritis Trials

ACR and EULAR Improvement Criteria Have Comparable Validity in Rheumatoid Arthritis Trials ACR and EULAR Improvement Criteria Have Comparable Validity in Rheumatoid Arthritis Trials ANKE M. van GESTEL, JENNIFER J. ANDERSON, PIET L.C.M. van RIEL, MAARTEN BOERS, CEES J. HAAGSMA, BILL RICH, GEORGE

More information

New Evidence reports on presentations given at EULAR 2012. Rituximab for the Treatment of Rheumatoid Arthritis

New Evidence reports on presentations given at EULAR 2012. Rituximab for the Treatment of Rheumatoid Arthritis New Evidence reports on presentations given at EULAR 2012 Rituximab for the Treatment of Rheumatoid Arthritis Report on EULAR 2012 presentations Long-term safety of rituximab: 10-year follow-up in the

More information

A critical review of foot orthoses in the rheumatoid arthritic foot

A critical review of foot orthoses in the rheumatoid arthritic foot Rheumatology 2006;45:139 145 Advance Access publication 8 November 2005 Review Article A critical review of foot orthoses in the rheumatoid arthritic foot H. Clark, K. Rome, M. Plant 1, K. O Hare y and

More information

Assessment of Medication Adherence in Rheumatoid Arthritis Patients

Assessment of Medication Adherence in Rheumatoid Arthritis Patients J.J. Appl. Sci. Vol. 10, No. 2 (2008) Assessment of Medication Adherence in Rheumatoid Arthritis Patients Kholoud Z. Qoul, Ikbal N. Thuheerat & Imad Al-Dogham Royal Medical Services, Amman, Jordan Received:

More information

Medical Policy Manual. Topic: Vectra DA Blood Test for Rheumatoid Arthritis Date of Origin: June 2014

Medical Policy Manual. Topic: Vectra DA Blood Test for Rheumatoid Arthritis Date of Origin: June 2014 Medical Policy Manual Topic: Vectra DA Blood Test for Rheumatoid Arthritis Date of Origin: June 2014 Section: Laboratory Last Reviewed Date: June 2014 Policy No: 67 Effective Date: September 1, 2014 IMPORTANT

More information

DIVISION OF RHEUMATOLOGY DEPARTMENT OF MEDICINE UNIVERSITY OF WESTERN ONTARIO POSTGRADUATE EDUCTION ORTHOPAEDIC OFF-SERVICE GOALS & OBJECTIVES

DIVISION OF RHEUMATOLOGY DEPARTMENT OF MEDICINE UNIVERSITY OF WESTERN ONTARIO POSTGRADUATE EDUCTION ORTHOPAEDIC OFF-SERVICE GOALS & OBJECTIVES DIVISION OF RHEUMATOLOGY DEPARTMENT OF MEDICINE UNIVERSITY OF WESTERN ONTARIO POSTGRADUATE EDUCTION ORTHOPAEDIC OFF-SERVICE GOALS & OBJECTIVES GOAL #1 develop the ability to order and understand interpretation

More information

Comparison of Long-Term Clinical Outcome With Etanercept Treatment and Adalimumab Treatment of Rheumatoid Arthritis With Respect to Immunogenicity

Comparison of Long-Term Clinical Outcome With Etanercept Treatment and Adalimumab Treatment of Rheumatoid Arthritis With Respect to Immunogenicity ARTHRITIS & RHEUMATISM Vol. 64, No. 12, December 2012, pp 3850 3855 DOI 10.1002/art.34680 2012, American College of Rheumatology Comparison of Long-Term Clinical Outcome With Etanercept Treatment and Adalimumab

More information

APPENDIX 1: INTERDISCIPLINARY APPROACH TO PREVENTION AND MANAGEMENT OF DIABETIC FOOT COMPLICATIONS

APPENDIX 1: INTERDISCIPLINARY APPROACH TO PREVENTION AND MANAGEMENT OF DIABETIC FOOT COMPLICATIONS APPENDIX 1: INTERDISCIPLINARY APPROACH TO PREVENTION AND MANAGEMENT OF DIABETIC FOOT COMPLICATIONS Template: Regional Foot Programs should develop a list of available health professionals in the following

More information

Improvement in Quality of Life of Rheumatoid Arthritis Patients on Biologic Therapy

Improvement in Quality of Life of Rheumatoid Arthritis Patients on Biologic Therapy Improvement in Quality of Life of Rheumatoid Arthritis Patients on Biologic Therapy R Adams 1, Ct Ng 2, A Gibbs 2, L Tilson 1, D Veale 2, B Bresnihan 2, O FitzGerald 2, M Barry 1 1. National Centre for

More information

BEDFORDSHIRE AND LUTON JOINT PRESCRIBING COMMITTEE (JPC)

BEDFORDSHIRE AND LUTON JOINT PRESCRIBING COMMITTEE (JPC) BEDFORDSHIRE AND LUTON JOINT PRESCRIBING COMMITTEE (JPC) September 2014 Review date: September 2017 Bulletin 203: Tocilizumab (subcutaneous) in combination with methotrexate or as monotherapy for the treatment

More information

A Patient s Guide to Arthritis of the Big Toe (Hallux Rigidus) With Discussion on Cheilectomy and Fusion

A Patient s Guide to Arthritis of the Big Toe (Hallux Rigidus) With Discussion on Cheilectomy and Fusion A Patient s Guide to Arthritis of the Big Toe (Hallux Rigidus) With Discussion on Cheilectomy and Fusion The foot and ankle unit at the Royal National Orthopaedic Hospital (RNOH) is a multi-disciplinary

More information

Rheumatoid Arthritis. Nicole Klett,, M.D.

Rheumatoid Arthritis. Nicole Klett,, M.D. Rheumatoid Arthritis Nicole Klett,, M.D. Rheumatoid Arthritis Systemic Chronic Inflammatory Primarily targets the synovium of diarthrodial joints Etiology likely combination genetic and environmental Diarthrodial

More information

Methods for Measuring Dose Escalation in TNF Antagonists for Rheumatoid Arthritis Patients Treated in Routine Clinical Practice

Methods for Measuring Dose Escalation in TNF Antagonists for Rheumatoid Arthritis Patients Treated in Routine Clinical Practice Methods for Measuring Dose Escalation in TNF Antagonists for Rheumatoid Arthritis Patients Treated in Routine Clinical Practice Gu NY 1, Huang XY 2, Globe D 2, Fox KM 3 1 University of Southern California,

More information

A Genetic Analysis of Rheumatoid Arthritis

A Genetic Analysis of Rheumatoid Arthritis A Genetic Analysis of Rheumatoid Arthritis Introduction to Rheumatoid Arthritis: Classification and Diagnosis Rheumatoid arthritis is a chronic inflammatory disorder that affects mainly synovial joints.

More information

Responsiveness of the Michigan Hand Outcomes Questionnaire - Dutch Language Version in Patients With Rheumatoid Arthritis

Responsiveness of the Michigan Hand Outcomes Questionnaire - Dutch Language Version in Patients With Rheumatoid Arthritis Chapter 5 Responsiveness of the Michigan Hand Outcomes Questionnaire - Dutch Language Version in Patients With Rheumatoid Arthritis Arch Phys Med Rehabil 2008; 89:1121-6 F.J. van der Giesen R.G.H.H. Nelissen

More information

RHEUMATOID ARTHRITIS. Dr Bruce Kirkham Rheumatology Clinical Lead

RHEUMATOID ARTHRITIS. Dr Bruce Kirkham Rheumatology Clinical Lead RHEUMATOID ARTHRITIS Dr Bruce Kirkham Rheumatology Clinical Lead RHEUMATOID ARTHRITIS (RA) RA is a common disease: 0.8 per cent of the population RA more common in females: female to male ratio 3:1 RA

More information

Once the immune system is triggered, cells migrate from the blood into the joints and produce substances that cause inflammation.

Once the immune system is triggered, cells migrate from the blood into the joints and produce substances that cause inflammation. HealthExchange Points For Your Joints An Arthritis Talk Howard Epstein, MD Orthopaedic & Rheumatologic Institute Rheumatic & Immunologic Disease Cleveland Clinic Beachwood Family Health & Surgery Center

More information

The new ACR/EULAR remission criteria: rationale for developing new criteria for remission

The new ACR/EULAR remission criteria: rationale for developing new criteria for remission RHEUMATOLOGY Rheumatology 2012;51:vi16 vi20 doi:10.1093/rheumatology/kes281 The new ACR/EULAR remission criteria: rationale for developing new criteria for remission Vivian P. Bykerk 1,2 and Elena M. Massarotti

More information

How To Treat Rheumatoid Arthritis

How To Treat Rheumatoid Arthritis RHEUMATOLOGY Rheumatology 2012;51:v48 v54 doi:10.1093/rheumatology/kes122 Developing an effective treatment algorithm for rheumatoid arthritis Edward C. Keystone 1, Josef Smolen 2 and Piet van Riel 3 Abstract

More information

Summary chapter 2 chapter 2

Summary chapter 2 chapter 2 Summary Multiple Sclerosis (MS) is a chronic disease of the brain and the spinal cord. The cause of MS is unknown. MS usually starts in young adulthood. In the course of the disease progression of neurological

More information

Prognostic factors in rheumatoid arthritis

Prognostic factors in rheumatoid arthritis Prognostic factors in rheumatoid arthritis Thesis Éva Palkonyai M.D. Semmelweis University, Budapest School of Ph.D. Studies Supervisor: Péter Gergely MD, D.Sci Budapest 2006. 1 Contents 1. Introduction

More information

Facts About Aging and Bone Health

Facts About Aging and Bone Health Facts About Aging and Bone Health A Guide to Better Understanding and Well Being with the compliments of Division of Health Services Diocese of Camden Exercise as treatment Along with medication, proper

More information

Position Statement: The Use of Total Ankle Replacement for the Treatment of Arthritic Conditions of the Ankle

Position Statement: The Use of Total Ankle Replacement for the Treatment of Arthritic Conditions of the Ankle Position Statement: The Use of Total Ankle Replacement for the Treatment of Arthritic Conditions of the Ankle Position Statement The (AOFAS) endorses the use of total ankle replacement surgery for treatment

More information

Critically evaluate the organization of diabetic foot ulcer services and interdisciplinary team working

Critically evaluate the organization of diabetic foot ulcer services and interdisciplinary team working Rationale of Module Accurate nursing assessment is the key to effective diabetic foot ulcer prevention, treatment and management. A comprehensive assessment identifies ulcer aetiology and the factors which

More information

The Burden of Rheumatoid

The Burden of Rheumatoid The Burden of Rheumatoid Arthritis (RA) and Patient Access to Treatment by prof. Bengt Jönsson, DR. Gisela Kobelt and PROF. Josef Smolen summary of key findings Table of contents Introduction Introduction

More information

Methotrexate Is Not Disease Modifying In Psoriatic Arthritis

Methotrexate Is Not Disease Modifying In Psoriatic Arthritis Methotrexate Is Not Disease Modifying In Psoriatic Arthritis A New Treatment Paradigm Is Required Gabrielle H Kingsley*, Jonathan Packham, Neil McHugh, Diarmuid Mulherin George Kitas, Kuntal Chakravarty,

More information

Morgan Schultz 1, Stephanie Keeling 2, Steven Katz 2, Walter Maksymowych 2, Dean Eurich 3, Jill Hall 1 1

Morgan Schultz 1, Stephanie Keeling 2, Steven Katz 2, Walter Maksymowych 2, Dean Eurich 3, Jill Hall 1 1 Morgan Schultz 1, Stephanie Keeling 2, Steven Katz 2, Walter Maksymowych 2, Dean Eurich 3, Jill Hall 1 1 Faculty of Pharmacy and Pharmaceutical Sciences, 2 Faciluty of Medicine and Dentistry, 3 School

More information

Latvian Early Intervention Concept development

Latvian Early Intervention Concept development Latvian Early Intervention Concept development Professor Daina Andersone, Medical Faculty of Latvian University Fit for Work Medical team leader in Latvia Latvian Presidency of the EU Council Healthcare

More information

to Part of Dossier: Name of Active Ingredient: Title of Study: Quality of life study with adalimumab in rheumatoid arthritis. ESCALAR.

to Part of Dossier: Name of Active Ingredient: Title of Study: Quality of life study with adalimumab in rheumatoid arthritis. ESCALAR. 2.0 Synopsis Abbott Laboratories Name of Study Drug: Individual Study Table Referring to Part of Dossier: Adalimumab (HUMIRA) (For National Authority Use Only) Name of Active Ingredient: Adalimumab Title

More information

Jill Malcolm, Karen Moir

Jill Malcolm, Karen Moir Evaluation of Fife- DICE: Type 2 diabetes insulin conversion Article points 1. Fife-DICE is an insulin conversion group education programme. 2. People with greater than 7.5% on maximum oral therapy are

More information

Benedikt Ostendorf, Axel Scherer, Ulrich Mödder, and Matthias Schneider

Benedikt Ostendorf, Axel Scherer, Ulrich Mödder, and Matthias Schneider ARTHRITIS & RHEUMATISM Vol. 50, No. 7, July 2004, pp 2094 2102 DOI 10.1002/art.20314 2004, American College of Rheumatology Diagnostic Value of Magnetic Resonance Imaging of the Forefeet in Early Rheumatoid

More information

8 General discussion. Chapter 8: general discussion 95

8 General discussion. Chapter 8: general discussion 95 8 General discussion The major pathologic events characterizing temporomandibular joint osteoarthritis include synovitis and internal derangements, giving rise to pain and restricted mobility of the temporomandibular

More information

Improved Survival in Psoriatic Arthritis With Calendar Time

Improved Survival in Psoriatic Arthritis With Calendar Time ARTHRITIS & RHEUMATISM Vol. 56, No. 8, August 2007, pp 2708 2714 DOI 10.1002/art.22800 2007, American College of Rheumatology Improved Survival in Psoriatic Arthritis With Calendar Time Yaser Ali, 1 Brian

More information

Outline. Personal profile & research interests. Rheumatology research in Ireland. Current standing. Future plans

Outline. Personal profile & research interests. Rheumatology research in Ireland. Current standing. Future plans Outline Personal profile & research interests Rheumatology research in Ireland Current standing Future plans Personal profile 1983 MB Queens University 1990-3 ARUK Clinical Research Fellowship 1990-93

More information

MEDICAL ASSISTANCE HANDBOOK PRIOR AUTHORIZATION OF PHARMACEUTICAL SERVICES `I. Requirements for Prior Authorization of Cytokine and CAM Antagonists

MEDICAL ASSISTANCE HANDBOOK PRIOR AUTHORIZATION OF PHARMACEUTICAL SERVICES `I. Requirements for Prior Authorization of Cytokine and CAM Antagonists MEDICAL ASSISTANCE HBOOK `I. Requirements for Prior Authorization of Cytokine and CAM Antagonists A. Prescriptions That Require Prior Authorization All prescriptions for Cytokine and CAM Antagonists must

More information